Comprehensive molecular portraits of human breast tumours. Cancer Genome Atlas Network (2012) Nature 490: 61-70 Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC (2001) J Clin Oncol 19: 3422-33 Treatment of HER2-positive breast cancer: current status and future perspectives. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L (2011) Nat Rev Clin Oncol 9: 16-32 Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, Gao YT, Jin F, Zheng W (2000) J Natl Cancer Inst 92: 412-7 The α₂β₁ integrin is a metastasis suppressor in mouse models and human cancer. Ramirez NE, Zhang Z, Madamanchi A, Boyd KL, O'Rear LD, Nashabi A, Li Z, Dupont WD, Zijlstra A, Zutter MM (2011) J Clin Invest 121: 226-37 Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL (2013) Proc Natl Acad Sci U S A 110: 14372-7 Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL (2002) Cancer Res 62: 4132-41 Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer? Arteaga CL (2011) Clin Cancer Res 17: 4919-21 H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL (2010) Oncogene 29: 5193-203 Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, Arteaga CL (2003) Mol Cell Biol 23: 8691-703 African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Jones BA, Kasl SV, Howe CL, Lachman M, Dubrow R, Curnen MM, Soler-Vila H, Beeghly A, Duan F, Owens P (2004) Cancer 101: 1293-301 ERBB2 genetic polymorphism and breast cancer risk in Chinese women: a population-based case-control study. Qu S, Cai Q, Gao YT, Lu W, Cai H, Su Y, Wang SE, Shu XO, Zheng W (2008) Breast Cancer Res Treat 110: 169-76 Farnesyltransferase inhibitor-induced regression of mammary tumors in TGF alpha and TGF alpha/neu transgenic mice correlates with inhibition of map kinase and p70s6 kinase phosphorylation. Nørgaard P, Law BK, Plovisson HS, Moses HL (1999) Ann N Y Acad Sci 886: 265-8 Inhibitors of HER2/neu (erbB-2) signal transduction. Arteaga CL, Chinratanalab W, Carter MB (2001) Semin Oncol 28: 30-5 HER-2/neu (erbB-2) and the cell cycle. Busse D, Doughty RS, Arteaga CL (2000) Semin Oncol 27: 3-8; discussion 92-100 Epidermal growth factor receptor dependence in human tumors: more than just expression? Arteaga CL (2002) Oncologist 7 Suppl 4: 31-9 Her-2/neu amplification and breast cancer survival: results from the Shanghai breast cancer study. Beeghly-Fadiel A, Kataoka N, Shu XO, Cai Q, Deming SL, Gao YT, Zheng W (2008) Oncol Rep 19: 1347-54 Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma. Persons DL, Arber DA, Sosman JA, Borelli KA, Slovak ML (2000) Anticancer Res 20: 1965-8
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.